Literature DB >> 20817787

Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.

Samantha K McCarty1, Motoyasu Saji, Xiaoli Zhang, David Jarjoura, Alfredo Fusco, Vasyl V Vasko, Matthew D Ringel.   

Abstract

p21-activated kinases (PAKs) are a family of serine/threonine kinases that regulate cytoskeletal dynamics and cell motility. PAKs are subdivided into group I (PAKs 1-3) and group II (PAKs 4-6) on the basis of structural and functional characteristics. Based on prior gene expression data that predicted enhanced PAK signaling in the invasive fronts of aggressive papillary thyroid cancers (PTCs), we hypothesized that PAKs functionally regulate thyroid cancer cell motility and are activated in PTC invasive fronts. We examined PAK isoform expression in six human thyroid cancer cell lines (BCPAP, KTC1, TPC1, FTC133, C643, and SW1746) by quantitative reverse transcription-PCR and western blot. All cell lines expressed PAKs 1-4 and PAK6 mRNA and PAKs 1-4 protein; PAK6 protein was variably expressed. Samples from normal and malignant thyroid tissues also expressed PAKs 1-4 and PAK6 mRNA; transfection with the group I (PAKs 1-3) PAK-specific p21 inhibitory domain molecular inhibitor reduced transwell filter migration by ∼50% without altering viability in all cell lines (P<0.05). BCPAP and FTC133 cells were transfected with PAK1, PAK2, or PAK3-specific small interfering RNA (siRNA); only PAK1 siRNA reduced migration significantly for both cell lines. Immunohistochemical analysis of seven invasive PTCs demonstrated an increase in PAK1 and pPAK immunoactivity in the invasive fronts versus the tumor center. In conclusion, PAK isoforms are expressed in human thyroid tissues and cell lines. PAK1 regulates thyroid cancer cell motility, and PAK1 and pPAK levels are increased in PTC invasive fronts. These data implicate PAKs as regulators of thyroid cancer invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817787      PMCID: PMC3717591          DOI: 10.1677/ERC-10-0168

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  43 in total

Review 1.  p21-activated kinases: three more join the Pak.

Authors:  Zahara M Jaffer; Jonathan Chernoff
Journal:  Int J Biochem Cell Biol       Date:  2002-07       Impact factor: 5.085

Review 2.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 3.  P21-activated kinases in human cancer.

Authors:  Ratna K Vadlamudi; Rakesh Kumar
Journal:  Cancer Metastasis Rev       Date:  2003-12       Impact factor: 9.264

4.  p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1).

Authors:  C C King; E M Gardiner; F T Zenke; B P Bohl; A C Newton; B A Hemmings; G M Bokoch
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

Review 5.  Emerging functions of p21-activated kinases in human cancer cells.

Authors:  Rakesh Kumar; Ratna K Vadlamudi
Journal:  J Cell Physiol       Date:  2002-11       Impact factor: 6.384

6.  Overexpression and overactivation of Akt in thyroid carcinoma.

Authors:  M D Ringel; N Hayre; J Saito; B Saunier; F Schuppert; H Burch; V Bernet; K D Burman; L D Kohn; M Saji
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

7.  The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity.

Authors:  M Thullberg; A Gad; A Beeser; J Chernoff; S Strömblad
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

8.  All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1.

Authors:  J Kurebayashi; K Tanaka; T Otsuki; T Moriya; H Kunisue; M Uno; H Sonoo
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

9.  Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1.

Authors:  L Adam; R Vadlamudi; M Mandal; J Chernoff; R Kumar
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

10.  High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Authors:  Xiulong Xu; Roderick M Quiros; Paolo Gattuso; Kenneth B Ain; Richard A Prinz
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  23 in total

Review 1.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

2.  Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Authors:  Hemant K Bid; Jun Zhan; Doris A Phelps; Raushan T Kurmasheva; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2011-12-21       Impact factor: 6.261

3.  RCAN1-4 is a thyroid cancer growth and metastasis suppressor.

Authors:  Chaojie Wang; Motoyasu Saji; Steven E Justiniano; Adlina Mohd Yusof; Xiaoli Zhang; Lianbo Yu; Soledad Fernández; Paul Wakely; Krista La Perle; Hiroshi Nakanishi; Neal Pohlman; Matthew D Ringel
Journal:  JCI Insight       Date:  2017-03-09

4.  MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Authors:  Christina M Knippler; Motoyasu Saji; Neel Rajan; Kyle Porter; Krista M D La Perle; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

5.  Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.

Authors:  Melania Ester Mercado-Pimentel; Craig Miller; Daniela N Rolph; Edrick F Villalobos; Allison M Dunn; Prithvi M Mohan; Suzu Igarashi; Xiangdang Liu; Macken Yrun-Duffy; Neal K Patel; Cecilia M Read; Ross H Francis; Adelina Isabella Lane; Swaroop Murugesh; Abraham Jacob
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

6.  Analysis of exosome release as a cellular response to MAPK pathway inhibition.

Authors:  K Agarwal; M Saji; S M Lazaroff; A F Palmer; M D Ringel; M E Paulaitis
Journal:  Langmuir       Date:  2015-05-05       Impact factor: 3.882

7.  Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.

Authors:  Yihui Ma; Samantha K McCarty; Naval P Kapuriya; Victoria J Brendel; Chaojie Wang; Xiaoli Zhang; David Jarjoura; Motoyasu Saji; Ching-Shih Chen; Matthew D Ringel
Journal:  J Clin Endocrinol Metab       Date:  2013-05-24       Impact factor: 5.958

8.  Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.

Authors:  Daphne R Pringle; Vasily V Vasko; Lianbo Yu; Parmeet K Manchanda; Audrey A Lee; Xiaoli Zhang; Jessica M Kirschner; Albert F Parlow; Motoyasu Saji; David Jarjoura; Matthew D Ringel; Krista M D La Perle; Lawrence S Kirschner
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

9.  Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Eman Emam; Wafaey Gomaa; Doaa Al-Qaydy; Basim Al-Maghrabi; Abdelbaset Buhmeida; Adel Abuzenadah; Mohammed Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 10.  Metastatic mechanisms in follicular cell-derived thyroid cancer.

Authors:  John E Phay; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2013-10-14       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.